Plain-English translation of NCT07690540 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This study is trying to understand why some patients with endometrial cancer respond well to immune checkpoint inhibitors (a type of immunotherapy), while others don't. Researchers will analyze tumor samples from about 510 patients to identify biological markers—like genetic and molecular fingerprints—that can help doctors predict which patients are most likely to benefit from this treatment before they start it.
Immune checkpoint inhibitors have improved treatment options for advanced endometrial cancer, but they don't work for everyone and can cause side effects. Right now, doctors don't have reliable ways to predict which patients will benefit, which means some people receive expensive treatment that won't help them. This study aims to find better predictive markers so doctors can match patients with the treatments most likely to work for them.
You likely qualify if…
You likely don't qualify if…
As a participant, you would provide tumor tissue samples that have already been collected during your cancer care—this is not an additional biopsy or procedure. Your samples will be analyzed using advanced laboratory techniques to examine genetic, molecular, and other biological features. The research team will study these samples to identify patterns that predict treatment response, and you may be asked to complete surveys or allow access to your medical records.
AI-generated summary from trial data · Jul 15, 2026 · Not medical advice
Italy